<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187339</url>
  </required_header>
  <id_info>
    <org_study_id>NGM395-OB-101</org_study_id>
    <nct_id>NCT04187339</nct_id>
  </id_info>
  <brief_title>Study of NGM395 in Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of NGM395 in adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>140 Days</time_frame>
    <description>The number and percent of patients reporting treatment emergent adverse events (TEAEs) by cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of NGM395</measure>
    <time_frame>140 Days</time_frame>
    <description>NGM395 concentration data by cohort</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>NGM395 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM395 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM395 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM395 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM395 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM395 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM395 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM395 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM395 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM395 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM395 Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM395 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM395</intervention_name>
    <description>NGM395 Dose 1</description>
    <arm_group_label>NGM395 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM395</intervention_name>
    <description>NGM395 Dose 2</description>
    <arm_group_label>NGM395 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM395</intervention_name>
    <description>NGM395 Dose 3</description>
    <arm_group_label>NGM395 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM395</intervention_name>
    <description>NGM395 Dose 4</description>
    <arm_group_label>NGM395 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM395</intervention_name>
    <description>NGM395 Dose 5</description>
    <arm_group_label>NGM395 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM395</intervention_name>
    <description>NGM395 Dose 6</description>
    <arm_group_label>NGM395 Dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1:

          1. Body mass index (BMI) in the range of 27 - 45 kg/m², inclusive, at screening, with
             maximum body weight of 140 kg.

             Part 2:

          2. Liver fat ≥8% as assessed by MRI-PDFF.

          3. BMI in the range of 27 - 45 kg/m2, inclusive, with maximum body weight of 140 kg at
             screening.

          4. Waist circumference &gt; 40 inches for males or &gt; 35 inches for females.

        Exclusion Criteria:

        Part 1:

          1. Diagnosed with type 2 diabetes (T2D) and/or the use of metformin, dipeptidyl
             peptidase-4 (DPP4) inhibitors, sodium/glucose cotransporter 2 (SGLT2) inhibitors,
             sulfonylurea agents, acarbose, or insulin for T2D within 3 months prior to Screening.

          2. Subjects with T2D managed with diet alone with HbA1c level &gt; 6.5% or fasting glucose ≥
             126 mg/dL at Screening.

          3. History of bariatric surgery.

          4. Fasting triglycerides &gt; 400 mg/dL at Screening.

             Part 2:

          5. Diagnosed with type 2 diabetes with a HbA1c &gt;9.5%, on thiazolidinediones,
             sodium/glucose cotransporter 2 (SGLT2) inhibitors, acarbose, or insulin for T2D within
             3 months prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pam Walentynowicz</last_name>
    <phone>650-243-5555</phone>
    <email>pwalentynowicz@ngmbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosa Paz</last_name>
    <phone>650-243-5555</phone>
    <email>rpaz@ngmbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

